COMBINATION THERAPY USING HDAC INHIBITOR

摘要

PROBLEM TO BE SOLVED: To provide a combination therapy using a histone deacetylase (HDAC) inhibitor, as an effective method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, prostate cancer, and epithelial ovarian cancer.SOLUTION: The method includes a step of administering a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as Tarceva (R), the first and second amounts or doses comprising a therapeutically effective amount. The combination effect is larger than the additive effect achieved by administering therapeutic doses of each of the two therapeutic agents.